POS-799 EFFECT OF DARATUMUMAB/BORTEZOMIB/CYCLOPHOSPHAMIDE/DEXAMETHASONE ON RENAL FUNCTION AND HRQOL IN PATIENTS WITH NEWLY-DIAGNOSED AL AMYLOIDOSIS WITH RENAL INVOLVEMENT: RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
| Autor: | N. Tran, A. Havasi, Shaji Kumar, Katharine S. Gries, Helen J. Lachmann, B.M. Weiss, X. Qin, Nelson Leung, A.J. Waxman, Vaishali Sanchorawala, Ashutosh D. Wechalekar, Huiling Pei |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Bortezomib business.industry Renal function Daratumumab Newly diagnosed medicine.disease Gastroenterology Diseases of the genitourinary system. Urology Nephrology Internal medicine medicine AL amyloidosis In patient RC870-923 Cyclophosphamide/Dexamethasone business medicine.drug |
| Zdroj: | Kidney International Reports, Vol 6, Iss 4, Pp S347-(2021) |
| ISSN: | 2468-0249 |
| DOI: | 10.1016/j.ekir.2021.03.832 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|